Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — A phase 3 trial of ulixacaltamide for essential ...

The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Success by nearly all measures with Praxis Precision Medicines Inc.’s essential tremor phase III candidate, ulixacaltamide, drove the company’s stock up by more than 200% and provided supportive data ...

100% (29/29) of patients experienced platelet count reduction to within normal ranges (150 – 400 x 109/L). 90% (26/29) of patients achieved a platelet count of less than 400 x 109/L without ...

Praxis Precision Medicines shares more than doubled in premarket trading Thursday after the clinical-stage biopharmaceutical reported positive topline results from a pair of late-stage studies of its ...

NORTH CHICAGO, Ill., Oct. 6, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) ...

DAVOS, Switzerland, Jan 17 (Reuters) - United Nations Secretary-General Antonio Guterres on Wednesday said the phase-out of fossil fuels was essential and inevitable to avoid a global climate ...